Next Generation Imbruvica Performs Well For Acerta In Early Studies

Acerta Pharma's second generation Bruton's tyrosine kinase (BTK) inhibitor, acalabrutinib (ACP-196), has proved itself to be a more selective, irreversible and improved version in early trials.